Publications

Search our bibliography using the filters on the right-hand side.

Displaying 351 through 400 of 699 publications.

Meyers J, Chaudhari P, Madhwani S, Candrilli SD. Clinical and economic burden of peripheral artery disease among patients receiving endovascular interventions: a retrospective cohort study of commercially insured patients in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A45.

Herring W, Mladsi DM. External validation of health economic models for complex chronic diseases: lessons from a population model for diabetic retinopathy. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A88.

Masaquel C, Jerusalem G, Copley-Merriman K, Ray D, Higuchi K, Caceres V. Economic burden of advanced breast cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A146.

Mordin M, Haydysch E, Graham-Clarke CP, Gnanasakthy A, Nikai E. Patient perceptions of psoriasis: a review of the survey literature by geography. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A126-7.

Mcbride D, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst A, Lacour J-P, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Proctor C, Sussman G, Weller K, Maurer M. ASSURE-CSU: assessing the impact of chronic spontaneous/idiopathic urticaria on work productivity and activity. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A124-5.

Abeysinghe SS, Le Moine JG, Margulis AV, Mauskopf JA. Frequentist and Bayesian meta-analysis of risk factors for respiratory syncytial virus hospitalization in preterm infants. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A174. doi: 10.1016/j.jval.2016.03.1458

Vickers AD. Survival network meta-analysis: hazard ratios versus reconstructed survival data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A90.

Goyal RK, Davis KL. Receipt of guideline-concordant surveillance care in elderly patients with colorectal cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A39.

Parikh RC, Du XL, Morgan RO, Lairson DR. Cost-effectiveness of treatment sequences for elderly metastatic colorectal cancer patients: a SEER-Medicare-based modeling analysis. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A150.

Tam IM, Candrilli SD, Moss JR. Characterizing emergency department utilization among pediatric patients with tympanostomy tubes. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A27.

Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.

Gnanasakthy A, Mordin M, Haydysch E, DeMuro C. FDA patient-reported outcome labeling of novel therapies (2011-2015). Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 25, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A285-6.

Gnanasakthy A, DeMuro C. Outcome assessments of primary endpoints of new drugs approved by the FDA (2011-2015). Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 25, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A275.

Brady B, Tkacz JMS, Nadipelli VR, Volpicelli J, Ronquest NA, Un H, Ruetsch C. Relapse in opioid use disorder: implications for healthcare utilization and costs. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A188.

Ghosh S, Kamal KM, Covvey JR, Candrilli SD, Giannetti V. Exploring the association between statins and COPD: an analysis of the 2009-2010 national health and nutrition examination survey. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A111.

Guminski A, Stull D, Houghton K, Gutzmer R, Migden MR, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Sellami D, Lear J, Dummer R. Change in fatigue and correlations with clinical outcome in patients with advanced basal cell carcinoma treated with sonidegib in the BOLT study. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A159.

Belozeroff V, Chertow GM, Graham CN, Dehmel D, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007

Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-effectiveness of chemotherapy for breast cancer and age effect in older women. Value Health. 2015 Dec;18(8):1070-8. doi: 10.1016/j.jval.2015.08.008

Candrilli S, Kurosky SK. Recent trends in anaphylaxis-related hospitalization in the United States. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A503.

Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.

Francois C, Danchenko N, Williams V, Nelson L, Williams NJ, Yarr S, DiBenedetti DB, Lancon C. Validation of the depression and family functioning scale (DFFS). Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A24.

Hogue S, Brogan AP, DeMuro C, Barrett A, D'Alessio D, Bal V. Influence of patient-reported outcomes on market access decisions in decentralized markets (Brazil, Italy, Spain, and the United States). Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A212.

Hogue SL, Bennett ME, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Wolf R, Wooddell M, White MV. Availability and use of epinephrine auto-injectors for the treatment of anaphylaxis: results from the EpiPen4Schools® survey. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A178. doi: 10.1016/j.jval.2015.03.1030

Mladsi DM, Goyal RK, Cryer B, Hopkins WE, Brater CD, Korsnes JS, Candrilli SD, Castellsague J, Varas-Lorenzo C. Risk of cardiovascular, gastrointestinal, and renal adverse events associated with diclofenac immediate and extended release drug products: an observational study using US claims data. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A292.

Mahida SR, Seoane E, Klinger E, Salazar A, HER QL, Medoff J, Amato M, Dykes PC, Haas J, Bates D, Schiff G. Cost of reporting possible adverse drug reactions in medical outpatients using a telephonic interactive voice response system. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 20, 2015. Philadelphia, PA. [abstract] Value Health. 2015 May 1; 18(3):PA257. doi: 10.1016/j.jval.2015.03.1498

Kurosky SK, Reese ES, Candrilli SD. Recent trends in bacterial infection-related hospitalizations in the United States. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A274.

Reese ES, Kurosky SK, Candrilli S. Recent trends in urgent antibacterial threat-related hospitalization in the US. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A234-5.

Goyal RK, Davis KL. Short- and long-term survival associated with laparoscopic versus open colectomy in early-stage colon cancer: findings from a retrospective cohort study. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A194.

Meyers JL, Candrilli SD. Common reasons for and associated burden of inpatient admissions among children in the United States. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A252-3.

Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.

Poulos C, Johnson FR, Krishnarajah F, Anonychuk A, Misurski D. Pediatricians' preferences for infant meningococcal vaccination. Value Health. 2015 Jan;18(1):67-77. doi: 10.1016/j.jval.2014.10.010

Petrillo J, Cano S, McLeod LD, Coon C. Using classical test theory, item response theory, and rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. Value Health. 2015 Jan;18(1):25-34. doi: 10.1016/j.jval.2014.10.005

Brogan AP, Hogue SL, Mordin MM, Kwong J. United States decision maker perceptions of data from observational studies and other health economics and outcomes research. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.

Doward L, Højbjerre L, Hogue S, Fernandez M, Barrett A, Crawford R, Kragh N, Aagren M. Influence of patient-reported outcomes on regulatory, HTA, and market access decisions: obesity and diabetes case examples. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.

Rothman M, Gnanasakthy A, Wicks P, Papadopoulos EJ. Can we use social media to support content validity of patient-reported outcome instruments in medical product development? Value Health. 2015 Jan;18(1):1-4. doi: 10.1016/j.jval.2014.10.001

Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.

Mahida S, Algarni M, Rittenhouse B. Effect of excluding non-patient benefits as an element on Acmg newborn screening (Nbs) recommendations. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 11, 2014. Amsterdam, Netherlands. [abstract] Value Health. 2014 Nov 1; 17(7):PA541. doi: 10.1016/j.jval.2014.08.1739

Novick D, Montgomery W, Aguado J, Duenas H, Haro JM. Symptomatic factors in patients with major depressive disorder (MDD): results from an observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A543.

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Comparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A766.

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A455.

Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.

Basarir H, Pollard D, Brennan A, Elliott J, Heller S, Campbell MJ. The potential value of ongoing support in type-1 diabetes mellitus with dafneplus: exploratory pre-trial cost-effectiveness analysis on proposed trial end-point target for 12-month Hba1c improvement. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A350. doi: 10.1016/j.jval.2014.08.725

Vass CM, Rigby D, Campbell S, Payne K. Investigating the framing-effects of risk attributes in discrete choice experiments: a pilot study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A648. doi: 10.1016/j.jval.2014.08.2349

McLeod L. Review of the Task Force Report on PRO data collection in clinical trials using mixed modes. Value Health. 2014 Jul;17(5):491-2. doi: 10.1016/j.jval.2014.06.003

Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl MG. Psychometric evaluation of the Psoriasis Symptom Diary using phase 3 trial data. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 Jun; 17(3):A288. doi: 10.1016/j.jval.2014.03.1676

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Parikh R, Taychakhoonavudh S, White C, Franzini L. Sources of spending variation in professional services among Texas Hospital Referral Regions: an analysis of private insurance population. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A18. doi: 10.1016/j.jval.2014.03.116

Hauber AB, Nguyen H, Posner JD, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (glp-1ra) injections in the treatment of type 2 diabetes. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A255.

Schwab PE, Saundankar V, Bouchard J, Moretz C, Baltz J. Delayed treatment modifications for patients with type 2 diabetes mellitus with very poor glycemic control. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 31, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3).

Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.